Braidwell’s Repligen RGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.6M Sell
47,500
-34,290
-42% -$4.79M 0.19% 81
2025
Q4
$13.4M Sell
81,790
-113,866
-58% -$17.8M 0.43% 61
2025
Q3
$26.2M Buy
195,656
+51,100
+35% +$6.21M 0.78% 38
2025
Q2
$18M Buy
144,556
+62,900
+77% +$8M 0.61% 42
2025
Q1
$10.4M Sell
81,656
-202,167
-71% -$31.1M 0.37% 50
2024
Q4
$40.9M Sell
283,823
-112,958
-28% -$16.2M 1.21% 34
2024
Q3
$59M Buy
396,781
+73,272
+23% +$10.5M 1.67% 24
2024
Q2
$40.8M Buy
323,509
+180,673
+126% +$28.3M 1.28% 33
2024
Q1
$26.3M Buy
142,836
+40,138
+39% +$7.64M 0.85% 43
2023
Q4
$18.5M Sell
102,698
-15,702
-13% -$2.44M 0.68% 44
2023
Q3
$18.8M Buy
118,400
+26,400
+29% +$4.32M 0.6% 57
2023
Q2
$13M Buy
+92,000
New +$14.8M 0.43% 66

Other funds holding RGEN

Braidwell's RGEN Position: Q1 2026 in Review

Braidwell reduced its Repligen (RGEN) stake by 42% in Q1 2026, selling an estimated $4.79M and leaving 47,500 shares worth $5.6M. The position accounts for 0.19% of the portfolio, ranked #81.

Braidwell first reported a position in RGEN in Q2 2023 and has held it in 12 quarters since. The position peaked at $59M in Q3 2024. 441 funds tracked by Wall St. Rank hold RGEN as of Q1 2026.

  • Braidwell held 47,500 shares of Repligen worth $5.6M as of Q1 2026.
  • Braidwell sold 34,290 Repligen shares in Q1 2026, an estimated $4.79M.
  • Repligen made up 0.19% of Braidwell's portfolio in Q1 2026, its #81 holding.
  • Braidwell first reported a position in Repligen in Q2 2023 and has held it in 12 quarters since.
  • Braidwell's Repligen position peaked at $59M in Q3 2024.
  • 441 funds tracked by Wall St. Rank held Repligen as of Q1 2026.

Based on Braidwell's 13F filing for Q1 2026, filed 15 May 2026.